英文标题：Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

中文标题：CheckMate816研究中辅助纳武利尤单抗联合化疗在可切除NSCLC患者中的总生存期（OS）

讲者：Patrick M. Forde, MD, PhD | Trinity St. James's Cancer Institute, Trinity College Dublin

英文标题：Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.

中文标题：新辅助（Neoadj）奥希替尼（Osi）联合或不联合化疗（CT）对比单纯化疗（CT）在可切除（R）表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）中的应用：NeoADAURA研究

讲者：Jamie E. Chaft, MD, FASCO | Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College

英文标题：Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.

中文标题：密西西比三角洲地区肺癌筛查（LCS）和偶然发现的肺部结节（IPN）队列中的肺癌诊断率（LCDR）

讲者：Raymond U. Osarogiagbon, MBBS, FACP, FASCO | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program

英文标题：SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.

中文标题：SWOG/NRG S1914：高风险早期NSCLC患者中诱导 / 巩固阿替利珠单抗联合SBRT 对比单纯SBRT的III期随机临床试验

讲者：Megan Eileen Daly, MD | Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center

英文标题：R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.

中文标题：R-ALPS：TQB2450联合或不联合安罗替尼作为维持治疗在经同步或序贯放化疗后无进展的局部晚期不可切除（Ⅲ期）非小细胞肺癌患者中的随机、双盲、安慰剂对照、多中心Ⅲ期临床试验

讲者：中山大学肿瘤防治中心  陈明

英文标题：Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).

中文标题：一项随机II期试验，研究放化疗（CRT）后使用阿替利珠单抗是否能延长局限期（LS）小细胞肺癌（SCLC）患者的生存期

讲者：Bjorn Henning Gronberg, MD, PhD | Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology and Department of Oncology, St. Olavs Hospital

英文标题：Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.

中文标题：芦比替定（lurbi）联合阿替利珠单抗（atezo）作为广泛期小细胞肺癌（ES-SCLC）患者的一线（1L）维持治疗：III期IMforte试验的主要结果

讲者：Luis G. Paz-Ares, MD, PhD | Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc

英文标题：A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.

中文标题：ZG006（一种靶向CD3/DLL3/DLL3的三特异性T细胞接合器）单药治疗晚期小细胞肺癌患者的II期剂量扩展研究

讲者：上海市胸科医院 艾星浩

英文标题：Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

中文标题：Tarlatamab对比化疗作为SCLC二线治疗：III期DeLLphi-304研究的主要分析

讲者：Charles M Rudin, MD, PhD | Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center

英文标题：Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

中文标题：III期AEGEAN试验中可切除非小细胞肺癌（R-NSCLC）患者术后MRD状态与新辅助ctDNA动态变化、基因组突变及临床结局的相关性

讲者：Martin Reck, MD, PhD | Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research

英文标题：Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T.

中文标题：CheckMate77T研究中围手术期纳武利尤单抗对比安慰剂用于可切除NSCLC患者的更新生存及生物标志物分析

讲者：Mariano Provencio, MD, PhD | Hospital Universitario Puerta de Hierro

英文标题：ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab

中文标题：基于ctDNA的MRD检测用于接受根治性放化疗联合度伐利尤单抗治疗的不可切除NSCLC患者

讲者：Aslaug Helland, MD, PhD | University of Oslo, Clinical Medicine

英文标题：The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).

中文标题：一项评估特瑞普利单抗联合诱导化疗，随后同步放化疗及特瑞普利单抗巩固治疗用于巨大不可切除的Ⅲ期非小细胞肺癌的随机II期试验的初步结果

讲者：中国医学科学院肿瘤医院   Yu Wang

英文标题：Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145)

中文标题：芦比替定联合阿替利珠单抗作为晚期小细胞肺癌二线治疗的安全性和有效性：Ⅰ/Ⅱ期2SMALL研究（NCT04253145）结果

讲者：Santiago Ponce Aix, MD, PhD | Hospital Universitario 12 de Octubre and Oncosur Foundation

英文标题：Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC)

中文标题：III期ADRIATIC试验中巩固度伐利尤单抗对比安慰剂用于同步放化疗（cCRT）后的LS-SCLC早期进展者（EPs）和长期无进展生存者（LTPs）的临床和分子特征

讲者：David Allen Barbie, MD | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

英文标题：Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).

中文标题：阿来替尼作为潜在可切除的III期ALK阳性NSCLC的新辅助治疗：ALNEO II期试验（GOIRC-01-2020-ML42316）最终分析

讲者：Marcello Tiseo | Department of Medicine and Surgery, University of Parma; Medical Oncology Unit, University Hospital of Parma; Gruppo Oncologico Italiano di Ricerca Clinica, GOIRC

英文标题：Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.

中文标题：纳武利尤单抗联合伊匹木单抗治疗经治的B3型胸腺瘤和胸腺癌患者的疗效和安全性：EORTC-ETOP NIVOTHYM II期试验结果

讲者：Nicolas Girard, MD, PhD | Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University

英文标题：Integrin α_Vβ₃-targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIIL study).

中文标题：整合素α_Vβ₃靶向成像用于肺癌识别及淋巴结转移灶定位：一项前瞻性、多中心、自身对照的Ⅲ期试验（TRIIL研究）

讲者：中国医学科学院北京协和医院 Rongxi Wang

英文标题：First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).

中文标题：首创新药PD-1/IL-2双特异性抗体IBI363用于治疗经免疫治疗的晚期非小细胞肺癌患者

讲者：浙江大学医学院附属第一院 周建娅

英文标题：Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study.

中文标题：MHB088C（一种新型靶向B7-H3的抗体偶联药物）在复发性广泛期小细胞肺癌（ES-SCLC）患者中的有效性和安全性：一项I/II期多中心研究的亚组分析

讲者：北京大学肿瘤医院 沈琳

英文标题：First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.

中文标题：首个评估BNT327/PM8002联合化疗作为不可切除恶性胸膜间皮瘤一线治疗的II期试验的疗效及安全性结果报告

讲者：吉林省肿瘤医院 程颖